title: [Treatment of intracoronary thrombus in the catheterisation laboratory in acute coronary syndrome patients].
abstract: Treatment of intracoronary thrombus is well documented. Three situations should be differentiated Primary percutaneous coronary intervention for early STEMI presenters is the most frequent one. Glycoprotein IIb/IIIa inhibitors are the gold standard antithrombotic treatment with a clear mortality benefit with abciximab. Thrombectomy with simple to use devices is another attractive option for interventionalists, although there is no clear established clinical benefit. Rescue PCI following failed thrombolysis is a more complicated situation given the underlying bleeding risk that is difficult to evaluate. The second situation is when a thrombus appears during an elective PCI. Although much less frequent than primary PCI, it is more often related to a lack of identification of the risk, to an inappropriate choice of the materials or to a non-optimal upstream antithrombotic treatment. A careful identification of all potential relevant causes is the key point of the management strategy. Post-PCI rethrombosis is the third situation and probably the less frequent. However, it is the most difficult to deal with.
authors.affiliation: Institut de cardiologie, centre hospitalier universitaire de la Pitié-Salpêtrière, APHP, 47, boulevard de l'Hôpital, 75013 Paris, France. jean-philippe.collet@psl.aphp.fr
authors.forename: J-P
authors.initials: JP
authors.lastname: Collet
authors.forename: F
authors.initials: F
authors.lastname: Beygui
authors.forename: O
authors.initials: O
authors.lastname: Barthélemy
authors.forename: B
authors.initials: B
authors.lastname: Livarek
authors.forename: G
authors.initials: G
authors.lastname: Montalescot
mesh_terms: D000077284:Abciximab; D054058:Acute Coronary Syndrome / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003328:Coronary Thrombosis / Q000628:therapy*; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006470:Hemorrhage / Q000517:prevention & control; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D018570:Risk Assessment; D015607:Stents; D017131:Thrombectomy; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab